Neurocrine Biosciences · 7 hours ago
Bioassay Scientist/Sr. Scientist, Analytical Development
San Diego, CA
Full-time
Onsite
Mid, Senior Level
$111K/yr - $151K/yr
5+ years expNeurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological disorders. The Bioassay Scientist/Sr. Scientist will act as the analytical potency subject matter expert, responsible for developing and managing potency assays to ensure key quality attributes are met throughout the drug development lifecycle.
BiotechnologyHealth CarePharmaceutical
Responsibilities
Lead potency methods development, and qualification/validation activities to support characterization of antibody and antibody conjugate modalities utilizing various bioassays including but not limited to cell-based assays, ELISA, TR-FRET, qPCR, and SPR
Design, execute, analyze, and interpret bioassay data for process intermediates, drug substance, and drug product across all development stages
Represent Analytical Development as potency SME on CMC cross-functional teams and maintain accountability for analytical deliverables
Support analytical method transfer, manufacturing support activities, and technical interactions with external vendors and contract laboratories
Lab Personnel and ensure laboratory safety practices
Leverage literature, ICH/Regulatory guidance, and practical experience to perform this work and influence CMC development strategies
Other duties as assigned
Qualification
Required
BS/BA degree in Biology or closely related field and 5+ years of pharmaceutical industry experience in an R&D/QC setting, including conducting bioassay analysis and troubleshooting, evaluating analytical data and drawing meaningful conclusions OR
MS/MA degree in Biology or closely related field and 3+ years of similar experience noted above OR
PhD in Biology or closely related field and some relevant experience; may include post-doc experience
Strong knowledge of analytical bioassays and antibody-based drug development preferred
Hands-on experience with antibody and bio-conjugate modalities, with emphasis on analytical development and potency methods
Proficient in bioassay technologies, including but not limited to: cell-based assays (e.g., proliferation, inhibition, cytotoxicity, reporter/luciferase), immunoassays (e.g., ELISA, TR-FRET), binding assays (e.g., SPR) and molecular biology assays (e.g., qPCR)
Method development, qualification, validation, and transfer experience in Analytical Development
Comprehensive understanding of cGMP requirements in drug substance and drug product
Expert knowledge of cross-functional understanding related to drug development
Knowledge of FDA, EMA, WHO, and ICH regulatory requirements
Excellent laboratory and productivity skills
Excellent interpersonal skills with strong oral and written communication abilities
Excellent problem solving and critical thinking skills
Benefits
Annual bonus with a target of 20% of the earned base salary
Eligibility to participate in our equity based long term incentive program
Retirement savings plan (with company match)
Paid vacation
Holiday and personal days
Paid caregiver/parental and medical leave
Health benefits to include medical, prescription drug, dental and vision coverage
Company
Neurocrine Biosciences
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
1001-5000 employees
H1B Sponsorship
Neurocrine Biosciences has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (16)
2024 (9)
2023 (8)
2022 (2)
2021 (5)
2020 (6)
Funding
Current Stage
Public CompanyTotal Funding
$260MKey Investors
Venrock
2015-02-19Post Ipo Equity· $250M
2009-12-17Post Ipo Equity· $10M
1996-05-31IPO
Leadership Team
Matt Abernethy
Chief Financial Officer
D
Dimitri Grigoriadis
VP, Research
Recent News
2026-01-06
Company data provided by crunchbase